Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura
- PMID: 36441262
- DOI: 10.1007/s00277-022-05049-6
Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura
Keywords: Anticoagulation; Caplacizumab; Hematology; Thrombotic thrombocytopenic purpura.
References
-
- Hollifield AL, Arnall JR, Moore DC (2020) Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. Am J Health Syst Pharm 77(15):1201–1207 - DOI
-
- Zheng XL, Vesely SK, Cataland SR et al (2020) ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. J Thromb Haemost 18:2486–2495. https://doi.org/10.1111/jth.15006 - DOI
-
- Elverdi T et al (2021) Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy? Expert Rev Clin Pharmacol 14:1183–1188 - DOI
-
- Peyvandi F et al (2016) Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med 374:511–522. https://doi.org/10.1056/JENMoa1505533 - DOI
-
- Scully M et al (2019) Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med 380:335–346. https://doi.org/10.1056/NEJMoa1806311 - DOI